ES470470A1 - Un procedimiento para la preparacion de ftalazinas - Google Patents

Un procedimiento para la preparacion de ftalazinas

Info

Publication number
ES470470A1
ES470470A1 ES470470A ES470470A ES470470A1 ES 470470 A1 ES470470 A1 ES 470470A1 ES 470470 A ES470470 A ES 470470A ES 470470 A ES470470 A ES 470470A ES 470470 A1 ES470470 A1 ES 470470A1
Authority
ES
Spain
Prior art keywords
piperidinophthalazines
cardiac stimulants
stimulants
cardiac
piperidinophthalazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES470470A
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp
Original Assignee
Pfizer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp filed Critical Pfizer Corp
Publication of ES470470A1 publication Critical patent/ES470470A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES470470A 1977-06-03 1978-06-02 Un procedimiento para la preparacion de ftalazinas Expired ES470470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2358277 1977-06-03

Publications (1)

Publication Number Publication Date
ES470470A1 true ES470470A1 (es) 1979-09-01

Family

ID=10198020

Family Applications (4)

Application Number Title Priority Date Filing Date
ES470470A Expired ES470470A1 (es) 1977-06-03 1978-06-02 Un procedimiento para la preparacion de ftalazinas
ES478201A Expired ES478201A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.
ES478200A Expired ES478200A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.
ES478199A Expired ES478199A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de etalazinas.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES478201A Expired ES478201A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.
ES478200A Expired ES478200A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de ftalazinas.
ES478199A Expired ES478199A1 (es) 1977-06-03 1979-03-01 Un procedimiento para la preparacion de etalazinas.

Country Status (29)

Country Link
US (1) US4289772A (US20030186963A1-20031002-C00026.png)
JP (1) JPS5416488A (US20030186963A1-20031002-C00026.png)
AR (2) AR222013A1 (US20030186963A1-20031002-C00026.png)
AT (2) AT362792B (US20030186963A1-20031002-C00026.png)
AU (1) AU505373B1 (US20030186963A1-20031002-C00026.png)
BE (1) BE867727A (US20030186963A1-20031002-C00026.png)
CA (1) CA1111850A (US20030186963A1-20031002-C00026.png)
DD (1) DD137355A5 (US20030186963A1-20031002-C00026.png)
DE (1) DE2824064A1 (US20030186963A1-20031002-C00026.png)
DK (1) DK248078A (US20030186963A1-20031002-C00026.png)
EG (1) EG13527A (US20030186963A1-20031002-C00026.png)
ES (4) ES470470A1 (US20030186963A1-20031002-C00026.png)
FI (1) FI781753A (US20030186963A1-20031002-C00026.png)
FR (1) FR2392986A1 (US20030186963A1-20031002-C00026.png)
GB (1) GB2000136B (US20030186963A1-20031002-C00026.png)
GR (1) GR74402B (US20030186963A1-20031002-C00026.png)
HU (1) HU179745B (US20030186963A1-20031002-C00026.png)
IL (1) IL54842A (US20030186963A1-20031002-C00026.png)
IN (3) IN148482B (US20030186963A1-20031002-C00026.png)
IT (1) IT1094944B (US20030186963A1-20031002-C00026.png)
LU (1) LU79761A1 (US20030186963A1-20031002-C00026.png)
NL (1) NL7806016A (US20030186963A1-20031002-C00026.png)
NO (1) NO781935L (US20030186963A1-20031002-C00026.png)
NZ (1) NZ187453A (US20030186963A1-20031002-C00026.png)
PL (3) PL116437B1 (US20030186963A1-20031002-C00026.png)
PT (1) PT68126A (US20030186963A1-20031002-C00026.png)
SE (1) SE7806519L (US20030186963A1-20031002-C00026.png)
SU (2) SU856383A3 (US20030186963A1-20031002-C00026.png)
ZA (1) ZA783183B (US20030186963A1-20031002-C00026.png)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370328A (en) * 1977-11-03 1983-01-25 Pfizer Inc. Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
IL59619A0 (en) * 1979-03-28 1980-06-30 Pfizer Phthalazine derivatives,their preparation and pharmaceutical compositions containing them
NZ196324A (en) * 1980-03-01 1983-09-02 Wyeth John & Brother Ltd Piperidine derivatives and pharmaceutical compositions piperidine and pyridinium intermediates
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4882354A (en) * 1987-12-16 1989-11-21 Norwich Eaton Pharmaceuticals, Inc. N-hydroxy-5-phenyl-2-furancarboximidamides useful as cardiotonic agents
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
US5300515A (en) * 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
EP0621267A1 (en) * 1993-04-07 1994-10-26 Shell Internationale Researchmaatschappij B.V. Spiropiperidine derivatives and their use as fungicides
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US6288064B1 (en) * 1996-08-20 2001-09-11 Eisai Co., Ltd. Remedy for erection failure comprising fused pyridazine compound
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
PT1539739E (pt) * 2002-08-16 2011-01-05 Janssen Pharmaceutica Nv Compostos de piperidinilo que ligam selectivamente integrinas
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
BRPI0707223A2 (pt) * 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP1903037A1 (de) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
BRPI0815658A2 (pt) 2007-08-07 2015-02-18 Hoffmann La Roche Aril-éter pirrolidina como antagonistas do receptor nk3
JP2010536818A (ja) 2007-08-22 2010-12-02 エフ.ホフマン−ラ ロシュ アーゲー Nk3受容体アンタゴニストとしてのピロリジンアリール−エーテル
JP2010539126A (ja) * 2007-09-14 2010-12-16 エフ.ホフマン−ラ ロシュ アーゲー Nk3受容体アンタゴニストとしてのピペリジン誘導体
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CN113087654B (zh) * 2021-04-15 2022-12-23 苏州昊帆生物股份有限公司 哌啶-4-丁胺的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
GB1199768A (en) 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
GB1460389A (en) 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants

Also Published As

Publication number Publication date
HU179745B (en) 1982-12-28
PL113208B1 (en) 1980-11-29
AR223999A1 (es) 1981-10-15
SU862826A3 (ru) 1981-09-07
IL54842A0 (en) 1978-08-31
AU505373B1 (en) 1979-11-15
ATA305080A (de) 1980-12-15
JPS5416488A (en) 1979-02-07
DK248078A (da) 1978-12-04
AT363096B (de) 1981-07-10
EG13527A (en) 1981-12-31
PL116437B1 (en) 1981-06-30
GB2000136A (en) 1979-01-04
ZA783183B (en) 1979-06-27
JPS5538351B2 (US20030186963A1-20031002-C00026.png) 1980-10-03
AT362792B (de) 1981-06-10
NZ187453A (en) 1980-12-19
PL207337A1 (pl) 1979-06-04
DD137355A5 (de) 1979-08-29
IT7824106A0 (it) 1978-06-01
ATA400878A (de) 1980-11-15
GB2000136B (en) 1982-01-06
IT1094944B (it) 1985-08-10
DE2824064A1 (de) 1978-12-14
GR74402B (US20030186963A1-20031002-C00026.png) 1984-06-28
AR222013A1 (es) 1981-04-15
BE867727A (fr) 1978-12-01
CA1111850A (en) 1981-11-03
ES478200A1 (es) 1980-01-01
LU79761A1 (fr) 1980-01-22
SU856383A3 (ru) 1981-08-15
NO781935L (no) 1978-12-05
NL7806016A (nl) 1978-12-05
IN148482B (US20030186963A1-20031002-C00026.png) 1981-03-07
PT68126A (en) 1978-07-01
IN149973B (US20030186963A1-20031002-C00026.png) 1982-06-19
FR2392986A1 (fr) 1978-12-29
FR2392986B1 (US20030186963A1-20031002-C00026.png) 1982-07-16
US4289772A (en) 1981-09-15
IL54842A (en) 1982-01-31
ES478201A1 (es) 1980-02-01
PL116420B1 (en) 1981-06-30
FI781753A (fi) 1978-12-04
SE7806519L (sv) 1978-12-04
ES478199A1 (es) 1980-01-16
IN149550B (US20030186963A1-20031002-C00026.png) 1982-01-16

Similar Documents

Publication Publication Date Title
ES478199A1 (es) Un procedimiento para la preparacion de etalazinas.
AU3905678A (en) Alph-halomethyl derivatives of amines
PH13955A (en) Novel heterocyclic derivatives of 1-(1,3-
JPS53137992A (en) Nnalkyllnnacyl derivative of thienamycine
AU517458B2 (en) Acetylenic derivatives of amines
IL53795A0 (en) Derivatives of thio-methylcarbamates
ZA783285B (en) New derivatives of amidinopenicillanic acid
AU514558B2 (en) Scale inhibitors
IL54608A0 (en) Derivatives of amino-alcohols
JPS53101769A (en) Hydroocyclone of radial multiistage type
GB2001074B (en) Cyclized derivatives of n-n-phosphonomethylglycine comp.
AU514875B2 (en) 17-acetylene derivatives of androst-4-ene
GB2000129B (en) Hydrazono derivatives of penicillins
GB2002748B (en) Cardiac stimulants
IL54308A0 (en) Derivatives of 9-fluoroprednisolone
ZA782927B (en) Cardiac stimulants
JPS5414862A (en) Production of steel desk
PH13855A (en) New derivatives of hydrasinium phosphite
JO884B1 (en) Amidinoformic acid
JPS53137993A (en) Nnalkyllnniminomethyl derivative of thienamycine
JPS5452098A (en) Methoion derivatives of pyrazolotriazilopyrimidines
ZA781643B (en) Derivatives of 9-fluoroprednisolone
KR790000539Y1 (en) Leather of fish-skin
SG1285G (en) Cardiac stimulants
BG25287A1 (en) Derivatives of trans-2-amino-3,5,8-trihydroxy-1,2,3,4-tetrahydronaphtalina